CA2234824A1 - Treatment of traumatic brain injury - Google Patents
Treatment of traumatic brain injury Download PDFInfo
- Publication number
- CA2234824A1 CA2234824A1 CA002234824A CA2234824A CA2234824A1 CA 2234824 A1 CA2234824 A1 CA 2234824A1 CA 002234824 A CA002234824 A CA 002234824A CA 2234824 A CA2234824 A CA 2234824A CA 2234824 A1 CA2234824 A1 CA 2234824A1
- Authority
- CA
- Canada
- Prior art keywords
- treatment
- ethyl
- tetrazol
- traumatic brain
- brain injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The compound 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine of formula (I) improves cognitive performance and attenuates injury-reduced reductions of cholinergic neurones in traumatic brain injury models and is useful for the manufacture of a pharmaceutical preparation for the treatment of traumatic brain injury.
Description
CA 02234824 l998-0~-Ol W O 97/17074 PCT~DK9G/00158 Tr~dl~"~nt of Traumatic Brain Injury Field of invention ";~ 5 The present invention relates to the use of 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetra-hydro-1-methylpyridine for manufacturing a pharmaceutical preparation for the treatment of traumatic brain injury (TBI).
Background of the Invention EP-A1 0 296 721 disclosed a class of piperidine or 1,2,3,6-terahydropyridine com-pounds substituted in the 5-position with a five-membered heterocyclic group includ-ing a subclass of optionally substituted 5-tetrazolyl-1,2,3,6-tetrahydro-pyridine com-pounds. The compounds were disclosed to have high affinity to central cholinergic receptors, in particular high affinity for central muscarinic M1 receptors, thus being useful in the treatment of Alzheimer's disease, senile dementia, and impaired learning and memory functions.
The structure-activity relationship of this subclass was described by Moltzen et al., J. Med. Chem. 1994, 37, 4085-4099. One of the compounds, i.e. 5-(2-ethyl-2H-tetra-zol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine has been reported to be selective for muscarinic receptors with a several fold higher affinity for M1 than for M2 and M3 receptors (Subtypes of Muscarinic Receptors, The Sixth Intemational Symposium, Nov. 9-12, 1994, Fort Lauderdale). Functionally, it has been described to behave as a partial agonist at M1 receptors and an antagonist at M2 and M3 receptors.
Furthermore, the only prominent in vivo effect reported was effect on spatial memory acquisition in young and aged rats, respectively.
TBI caused by physical or neurological conditions or various diseases is of in-30 creasing importance among the population and there is a great demand for effective and safe drugs for the treatment of such disorders and the sequelae thereof.
It has now surprisingly been found that the compound 5-(2-ethyl-2H-tetrazol-5-yl)-CONFIRMATION COPY
CA 02234824 1998-0C.-01 WO 97/17074 PCT/DK9~ 8 1,2,3,6-tetrahydro-1-methylpyridine shows beneficial effects in the treatment of TBI
and the sequelae thereof.
Summary of the Invention Accordingly, the present invention relates to the use of 5-(2-ethyl-2H-tetrazol-5-yl)-1 ,2,3,6-tetrahydro-1-methylpyridine or an acid addition salt thereof ~N~N
r N--for the manufacture of a pharmaceutical preparation for the treatment of traumatic brain injury or sequelae thereof.
The term traumatic brain injury (TBI) is in this specification meant to include all 15 conditions associated with trauma to the brain or spinal cord e.g. caused by physical forces acting on the scull or spinal column, ischaemia, stroke, arrested breathing, cardiac arrest, cerebral thrombosis or embolism, neurological problems caused byAIDS, cerebral hemorrhage, encephalomyelitis, hydrocephalus, post-operative events, cerebral infections, concussions or elevated intracranial pressure.
The pharmaceutically acceptable acid addition salts of the compounds used in theinvention are salts formed with non-toxic organic or inorganic acids. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, pamoic, suc-cinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propi-25 onic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic,aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sul-fonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromo-theophylline. Exemplary of such inorganic salts are those with hydrochlo-ric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.
CA 02234824 1998-0C,-01 The compound used according to the invention has now been found to be useful in the treatment of TBI. So, for example it improves cognitive performance following to moderate traumatic brain injury and it attenuates injury-reduced reductions of cholinergic neurones. Furthermore it has been found not to cause adverse cardiac5 or other side effects in doses believed to be clinically relevant.
In another aspect, the present invention provides a method for the prevention ortreatment of TBI in man comprising the step of administering a therapeutically effective amount of 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine 10 or acid addition salt thereof to a patient in need thereof.
The compound used according to the invention and the pharmaceutically accep-table acid addition salts thereof may be administered in any suitable way, e.g. orally or parenterally, and the compounds may be presented in any suitable form for such 15 administration, eg. in the form of tablets, capsules, powders, syrups or solutions or dispersions for injection.
An effective daily dose of the compound according to the invention or a pharmaceuti-cally acceptable salt thereof is from 10 ,ug/kg to 10 mg/kg body weight, preferably 20 25 ~g/day/kg body weight to 1.0 mg/day/kg body weight. Accordingly, a suitable daily dose is 500 ,ug to 600 mg/day, preferably 1.0 mg to 100 mg.
The compound used according to the invention may be obtained as described in EP-A1 0 296 721 and the acid addition salts thereof are easily prepared by methods 25 well known in the art.
Pharmacology The compound used according to the invention was tested by the following well ~ recognized and reliable method:
Cognitive Function following to TBI
Rats were subjected to central fluid percussion traumatic brain injury as described by Dixon, C.E., et al., J. Neurosurgery, 67 (1987) 110- 119. The injured animalswere treated s.c. daily on days 1-15 postinjury beginning 24 hours after injury with CA 02234824 1998-0~-01 W O 97/17074 PCT~DK~6/00458 either saline or 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine, 3.6 ,~Lmol/kg or 15 ~lmoVkg.
Righting reflex suppression after TBI was determined according to the method of Dixon et al.1987, supra.
Body weight was recorded prior to injury and on Days 1-5 postinjury and rotarod performance was determined on Days 1-5 post injury according to the method of Hamm, R.J., et al., J. Neurotrauma, 11 (1994) 187-196. The rotarod test was used to measure motor performance following TBI.
Finally, mean latency (+S.E.M.) to find the goal platform in the Morris water maze was measured on days 11-15 postinjury. The results were analysed by an ANOVA.
During the water maze testing all animals were injected 10 minutes prior to assess-ment in the water maze.
Shaminjured animals (animals prepared for injury but not delivered a fluid pulse)were included for comparison.
Qantification of ChATneurones following to TBI
Rats were subjected to central fluid percussion TBI and treated as described above.
They were injected s.c. with saline (n=5) or test compound (5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1 -methylpyridine, 15 ~Lmol/kg) (n=5) . Shaminjured rats were injected (s.c.) with saline (n=4) or test compound 15,umol/kg (n=4).
Righting reflex suppression was determined as described above.
Possible loss of cholinergic neurones following to TBI was determined by quantifica-tion of choline acethyltransferase (ChAT) immunoreactivity neurones in basal fore-brain. On day 15 post-injury (2-4 hours following last injection) all animals were ane-sthetized with pentobarbital (90 mg/kg, i.p.) and perfused transaortically with 200-250 ml of isotonic saline followed by 500 ml of 4.0% paraformaldehyde/0.2% picric acid in 0.1 M phosphate buffer at a rate of 500 ml/30 min at room temperature.
Following perfusion, brains were trimmed into two blocks and postfixed for 24 hours CA 02234824 l998-0~-Ol W O 97/17074 PCTADK~Gil~1~8 in the same solution at 10 ~C. Coronal 40 ,um sections were coilected on a vibra-tome through the forebrain nuclei and every fifth section was processed for ChATimmunoreactivity. Parallel sections were stained for Nissi substance with cresylviolet for quantitative assesment of any possible cholinergic and non-cholinergic neuronal loss in the basal forebrain nuclei.
Free floating forebrain sections were incubated in a final ChAT antibody concentra-tion (1 :50) of 1.0 ~g/ml in a 0.01 M phosphate buffered saline (PBS) solution contain-ing 0.1% triton X-100. The forebrain sections were trimmed and incubated in the pri-mary antibody for 24 hours at room temperature in culture trays (4 sections/300,~LL/well).
After 4 washes in PBS, the sections were incubated in the secondary antibody (horse antimouse IgG; Vector Laboratories, Burlingame, CA) for 1 hour at 37~C.
After 3 washes in PBS, the sections were incubated with mouse avidin-biotin-peroxi-dase complex (ABC) (Vector) technique (Hsu et al J. Histochem. Cytochem. 29, 1981, 577-580) for 2 hours at 37~C. Following three washes with PBS and one in 0.1M Tris-buffered saline (TBS), free floating sections were processed by the gucose oxidase-diaminobezidine-nickel method described by Shu et al. Neurosci.
Left. 85 1988, 169-171. The reaction was stopped by transferring the sections into TBS. The sections were mounted on gelatin-chrome alum coated glass slides and allowed to dry overnight at room temperature, dehydrated in ascending concentra-tions of ethanol and xylene, and then coverslipped with Permount.
The ChAT immunoreactive neurones in the medial septal nucleus (MSN), the vertical limb nucleus of the diagonal band (VDB) and the nucleus basalis magnocel-lularis (NMB) were counted using a Microcomputer Imaging Device system (MCID) (Imaging Research Inc., Ontario, Canada). The boundary between MSN and VDB
was defined as the anterior commisure. The NMB was defined as the imunolabelled neurons located in the globulus pallidus and the adjoining part of the internal capsule. Celle counts were made from each animal obtained at 0.2 mm intervals through the forebrain nuclei. Cell numbers are reported as group means per 10,000 ,um2 for each forebrain nucleus.
CA 02234824 1998-0~-01 Neurons of the MSN, VDB and NMB from parallel sections stained for cresyl violetwere aiso counted on the MCID. Because of the large number of the total choliner-gic and non-cholinergic neurons that stain for cresyl violet throughout these regions, ~ a bilatetral sample of beurons was couted in each nucleus. A grid with predeter-mined areas was used to count cells for each nucleus, For MSN and VDB nuclei, three 2,000 ,um2 regions were counted on each side (thus a total area of 12,000 m2 was sampled for each nucleus in each of the four section counted). For the NMB, one 12,000 ~m2 region was counted on each side (total area=24,000 ,um2 in each of the four section counted). Only large cells (>20 ,um diameter) with visible somatic Nissi bodies and with a clear neuronal type nucleus were quantified.
Results There were no significant differences between any of the injured animals on righting reflex suppression after TBI. This indicates that within each experiment the injury groups received an equivalent severity of injury. Sham-injured animals righted significantly faster than any of the TBI animals (p < 0.0001 for each comparison).
Suppression of righting in the sham-injured group is due to the gas anesthesia used prior to injury.
There was no significant difference between any of the injured groups on loss ofbody weight following TBI, again indicating an equivalent injury severity between injured groups.
There were no significant differences on rotarod performance on Days 1-5 post injury between any of the injured groups. Because test compound was administeredon Days 1-15 postinjury, these tests also indicate that the drug had no effect on body weight or rotarod performance following injury.
ANOVA indicated that the injured animals injected (s.c.) daily with test compound performed better in Morris water maze than injured saline treated animals. Injured animals treated with test compound 15 ~lmol/kg significantly improved performance with p ~ 0.01.
CA 02234824 1998-0~-01 W O 97/17074 PCT~DK~G/00158 TBi caused a significant reduction in the number of ChAT-lR neurons in VDB and NMB in rats treated with saline and test compound, respectively. However, the compound of the invention significally attenuated injury reduced reductions in ChAT-~ IR (32% reduction as compared to injured saline treated group in VDB and 51% in NMB). The parallel cresyl violet stained sections showed no decrease in cell numbers in the MSN, VDB or NMB indicating that the loss in ChAT-lR neurons does not result from cell death.
Formulation EXa~
The pharmaceutical formulations of the invention may be prepared by conventionalmethods in the art.
For example: Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conven-tional tabletting machine. Examples of adjuvants or diluents comprise: corn starch,lactose, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvant or additive colourings, aroma, preservatives etc. may be used provided that they are compatible with the active ingredients.
Solutions for injections may be prepared by solving the active ingredient and possible additives in a part of the vehicle, preferably sterile water, adjusting the solution to the desired volume, sterilization of the solution and filling in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.
Typical examples of recipes for the formulations of the invention are as follows(amounts of active ingredient calculated as the free base):
1 ) Tablets:
~ 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methyl-pyridine 20 mg Lactose 60 mg Maize starch 30 mg Hydroxypropylcellulose 2.4 mg Microcrystalline cellulose 19.2 mg CA 02234824 1998-0~-01 W O 97/17074 . PCT~DK9G/00~58 Croscarmellose Sodium Type A 2.4 mg Magnesium stearate 0.84 mg 2) Tablets:
5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methyl-pyridine 10 mg Lactose 46.9 mg Maize starch 23.5 mg Povidone 1.8 mg Microcrystalline cellulose 14.4 mg Croscarmellose Sodium Type A 1.8 mg Magnesium stearate 0.63 mg 3) Syrup:
5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methyl pyridine 5.0 mg Sorbitol 500 mg Hydroxypropylcellulose 15 mg Glycerol 50 mg Methyl-paraben 1 mg Propyl-paraben 0.1 mg Ethanol 0.005 ml Flavour 0.05 mg Saccharin natrium 0.5 mg Water ad 1 ml 4) Solution:
Background of the Invention EP-A1 0 296 721 disclosed a class of piperidine or 1,2,3,6-terahydropyridine com-pounds substituted in the 5-position with a five-membered heterocyclic group includ-ing a subclass of optionally substituted 5-tetrazolyl-1,2,3,6-tetrahydro-pyridine com-pounds. The compounds were disclosed to have high affinity to central cholinergic receptors, in particular high affinity for central muscarinic M1 receptors, thus being useful in the treatment of Alzheimer's disease, senile dementia, and impaired learning and memory functions.
The structure-activity relationship of this subclass was described by Moltzen et al., J. Med. Chem. 1994, 37, 4085-4099. One of the compounds, i.e. 5-(2-ethyl-2H-tetra-zol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine has been reported to be selective for muscarinic receptors with a several fold higher affinity for M1 than for M2 and M3 receptors (Subtypes of Muscarinic Receptors, The Sixth Intemational Symposium, Nov. 9-12, 1994, Fort Lauderdale). Functionally, it has been described to behave as a partial agonist at M1 receptors and an antagonist at M2 and M3 receptors.
Furthermore, the only prominent in vivo effect reported was effect on spatial memory acquisition in young and aged rats, respectively.
TBI caused by physical or neurological conditions or various diseases is of in-30 creasing importance among the population and there is a great demand for effective and safe drugs for the treatment of such disorders and the sequelae thereof.
It has now surprisingly been found that the compound 5-(2-ethyl-2H-tetrazol-5-yl)-CONFIRMATION COPY
CA 02234824 1998-0C.-01 WO 97/17074 PCT/DK9~ 8 1,2,3,6-tetrahydro-1-methylpyridine shows beneficial effects in the treatment of TBI
and the sequelae thereof.
Summary of the Invention Accordingly, the present invention relates to the use of 5-(2-ethyl-2H-tetrazol-5-yl)-1 ,2,3,6-tetrahydro-1-methylpyridine or an acid addition salt thereof ~N~N
r N--for the manufacture of a pharmaceutical preparation for the treatment of traumatic brain injury or sequelae thereof.
The term traumatic brain injury (TBI) is in this specification meant to include all 15 conditions associated with trauma to the brain or spinal cord e.g. caused by physical forces acting on the scull or spinal column, ischaemia, stroke, arrested breathing, cardiac arrest, cerebral thrombosis or embolism, neurological problems caused byAIDS, cerebral hemorrhage, encephalomyelitis, hydrocephalus, post-operative events, cerebral infections, concussions or elevated intracranial pressure.
The pharmaceutically acceptable acid addition salts of the compounds used in theinvention are salts formed with non-toxic organic or inorganic acids. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, pamoic, suc-cinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propi-25 onic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic,aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sul-fonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromo-theophylline. Exemplary of such inorganic salts are those with hydrochlo-ric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.
CA 02234824 1998-0C,-01 The compound used according to the invention has now been found to be useful in the treatment of TBI. So, for example it improves cognitive performance following to moderate traumatic brain injury and it attenuates injury-reduced reductions of cholinergic neurones. Furthermore it has been found not to cause adverse cardiac5 or other side effects in doses believed to be clinically relevant.
In another aspect, the present invention provides a method for the prevention ortreatment of TBI in man comprising the step of administering a therapeutically effective amount of 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine 10 or acid addition salt thereof to a patient in need thereof.
The compound used according to the invention and the pharmaceutically accep-table acid addition salts thereof may be administered in any suitable way, e.g. orally or parenterally, and the compounds may be presented in any suitable form for such 15 administration, eg. in the form of tablets, capsules, powders, syrups or solutions or dispersions for injection.
An effective daily dose of the compound according to the invention or a pharmaceuti-cally acceptable salt thereof is from 10 ,ug/kg to 10 mg/kg body weight, preferably 20 25 ~g/day/kg body weight to 1.0 mg/day/kg body weight. Accordingly, a suitable daily dose is 500 ,ug to 600 mg/day, preferably 1.0 mg to 100 mg.
The compound used according to the invention may be obtained as described in EP-A1 0 296 721 and the acid addition salts thereof are easily prepared by methods 25 well known in the art.
Pharmacology The compound used according to the invention was tested by the following well ~ recognized and reliable method:
Cognitive Function following to TBI
Rats were subjected to central fluid percussion traumatic brain injury as described by Dixon, C.E., et al., J. Neurosurgery, 67 (1987) 110- 119. The injured animalswere treated s.c. daily on days 1-15 postinjury beginning 24 hours after injury with CA 02234824 1998-0~-01 W O 97/17074 PCT~DK~6/00458 either saline or 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine, 3.6 ,~Lmol/kg or 15 ~lmoVkg.
Righting reflex suppression after TBI was determined according to the method of Dixon et al.1987, supra.
Body weight was recorded prior to injury and on Days 1-5 postinjury and rotarod performance was determined on Days 1-5 post injury according to the method of Hamm, R.J., et al., J. Neurotrauma, 11 (1994) 187-196. The rotarod test was used to measure motor performance following TBI.
Finally, mean latency (+S.E.M.) to find the goal platform in the Morris water maze was measured on days 11-15 postinjury. The results were analysed by an ANOVA.
During the water maze testing all animals were injected 10 minutes prior to assess-ment in the water maze.
Shaminjured animals (animals prepared for injury but not delivered a fluid pulse)were included for comparison.
Qantification of ChATneurones following to TBI
Rats were subjected to central fluid percussion TBI and treated as described above.
They were injected s.c. with saline (n=5) or test compound (5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1 -methylpyridine, 15 ~Lmol/kg) (n=5) . Shaminjured rats were injected (s.c.) with saline (n=4) or test compound 15,umol/kg (n=4).
Righting reflex suppression was determined as described above.
Possible loss of cholinergic neurones following to TBI was determined by quantifica-tion of choline acethyltransferase (ChAT) immunoreactivity neurones in basal fore-brain. On day 15 post-injury (2-4 hours following last injection) all animals were ane-sthetized with pentobarbital (90 mg/kg, i.p.) and perfused transaortically with 200-250 ml of isotonic saline followed by 500 ml of 4.0% paraformaldehyde/0.2% picric acid in 0.1 M phosphate buffer at a rate of 500 ml/30 min at room temperature.
Following perfusion, brains were trimmed into two blocks and postfixed for 24 hours CA 02234824 l998-0~-Ol W O 97/17074 PCTADK~Gil~1~8 in the same solution at 10 ~C. Coronal 40 ,um sections were coilected on a vibra-tome through the forebrain nuclei and every fifth section was processed for ChATimmunoreactivity. Parallel sections were stained for Nissi substance with cresylviolet for quantitative assesment of any possible cholinergic and non-cholinergic neuronal loss in the basal forebrain nuclei.
Free floating forebrain sections were incubated in a final ChAT antibody concentra-tion (1 :50) of 1.0 ~g/ml in a 0.01 M phosphate buffered saline (PBS) solution contain-ing 0.1% triton X-100. The forebrain sections were trimmed and incubated in the pri-mary antibody for 24 hours at room temperature in culture trays (4 sections/300,~LL/well).
After 4 washes in PBS, the sections were incubated in the secondary antibody (horse antimouse IgG; Vector Laboratories, Burlingame, CA) for 1 hour at 37~C.
After 3 washes in PBS, the sections were incubated with mouse avidin-biotin-peroxi-dase complex (ABC) (Vector) technique (Hsu et al J. Histochem. Cytochem. 29, 1981, 577-580) for 2 hours at 37~C. Following three washes with PBS and one in 0.1M Tris-buffered saline (TBS), free floating sections were processed by the gucose oxidase-diaminobezidine-nickel method described by Shu et al. Neurosci.
Left. 85 1988, 169-171. The reaction was stopped by transferring the sections into TBS. The sections were mounted on gelatin-chrome alum coated glass slides and allowed to dry overnight at room temperature, dehydrated in ascending concentra-tions of ethanol and xylene, and then coverslipped with Permount.
The ChAT immunoreactive neurones in the medial septal nucleus (MSN), the vertical limb nucleus of the diagonal band (VDB) and the nucleus basalis magnocel-lularis (NMB) were counted using a Microcomputer Imaging Device system (MCID) (Imaging Research Inc., Ontario, Canada). The boundary between MSN and VDB
was defined as the anterior commisure. The NMB was defined as the imunolabelled neurons located in the globulus pallidus and the adjoining part of the internal capsule. Celle counts were made from each animal obtained at 0.2 mm intervals through the forebrain nuclei. Cell numbers are reported as group means per 10,000 ,um2 for each forebrain nucleus.
CA 02234824 1998-0~-01 Neurons of the MSN, VDB and NMB from parallel sections stained for cresyl violetwere aiso counted on the MCID. Because of the large number of the total choliner-gic and non-cholinergic neurons that stain for cresyl violet throughout these regions, ~ a bilatetral sample of beurons was couted in each nucleus. A grid with predeter-mined areas was used to count cells for each nucleus, For MSN and VDB nuclei, three 2,000 ,um2 regions were counted on each side (thus a total area of 12,000 m2 was sampled for each nucleus in each of the four section counted). For the NMB, one 12,000 ~m2 region was counted on each side (total area=24,000 ,um2 in each of the four section counted). Only large cells (>20 ,um diameter) with visible somatic Nissi bodies and with a clear neuronal type nucleus were quantified.
Results There were no significant differences between any of the injured animals on righting reflex suppression after TBI. This indicates that within each experiment the injury groups received an equivalent severity of injury. Sham-injured animals righted significantly faster than any of the TBI animals (p < 0.0001 for each comparison).
Suppression of righting in the sham-injured group is due to the gas anesthesia used prior to injury.
There was no significant difference between any of the injured groups on loss ofbody weight following TBI, again indicating an equivalent injury severity between injured groups.
There were no significant differences on rotarod performance on Days 1-5 post injury between any of the injured groups. Because test compound was administeredon Days 1-15 postinjury, these tests also indicate that the drug had no effect on body weight or rotarod performance following injury.
ANOVA indicated that the injured animals injected (s.c.) daily with test compound performed better in Morris water maze than injured saline treated animals. Injured animals treated with test compound 15 ~lmol/kg significantly improved performance with p ~ 0.01.
CA 02234824 1998-0~-01 W O 97/17074 PCT~DK~G/00158 TBi caused a significant reduction in the number of ChAT-lR neurons in VDB and NMB in rats treated with saline and test compound, respectively. However, the compound of the invention significally attenuated injury reduced reductions in ChAT-~ IR (32% reduction as compared to injured saline treated group in VDB and 51% in NMB). The parallel cresyl violet stained sections showed no decrease in cell numbers in the MSN, VDB or NMB indicating that the loss in ChAT-lR neurons does not result from cell death.
Formulation EXa~
The pharmaceutical formulations of the invention may be prepared by conventionalmethods in the art.
For example: Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conven-tional tabletting machine. Examples of adjuvants or diluents comprise: corn starch,lactose, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvant or additive colourings, aroma, preservatives etc. may be used provided that they are compatible with the active ingredients.
Solutions for injections may be prepared by solving the active ingredient and possible additives in a part of the vehicle, preferably sterile water, adjusting the solution to the desired volume, sterilization of the solution and filling in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.
Typical examples of recipes for the formulations of the invention are as follows(amounts of active ingredient calculated as the free base):
1 ) Tablets:
~ 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methyl-pyridine 20 mg Lactose 60 mg Maize starch 30 mg Hydroxypropylcellulose 2.4 mg Microcrystalline cellulose 19.2 mg CA 02234824 1998-0~-01 W O 97/17074 . PCT~DK9G/00~58 Croscarmellose Sodium Type A 2.4 mg Magnesium stearate 0.84 mg 2) Tablets:
5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methyl-pyridine 10 mg Lactose 46.9 mg Maize starch 23.5 mg Povidone 1.8 mg Microcrystalline cellulose 14.4 mg Croscarmellose Sodium Type A 1.8 mg Magnesium stearate 0.63 mg 3) Syrup:
5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methyl pyridine 5.0 mg Sorbitol 500 mg Hydroxypropylcellulose 15 mg Glycerol 50 mg Methyl-paraben 1 mg Propyl-paraben 0.1 mg Ethanol 0.005 ml Flavour 0.05 mg Saccharin natrium 0.5 mg Water ad 1 ml 4) Solution:
5-(2-ethyl-2H-tetrazol-5-yl)-1 ,2,3,6-tetrahydro-1 -methyl-pyridine 1.0 mg Sorbitol 5.1 mg Acetic acid 0.08 mg Water for injection ad 1 ml
Claims (4)
1. Use of 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine or a pharmaceutically acceptable acid addition salt thereof for the manufacture of a pharmaceutical preparation for the treatment of traumatic brain injury.
2. Use according to any of claim 1, characterised in that the pharmaceutical preparation manufactured comprises 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-1-methylpyridine or a pharmaceutically acceptable acid addition salt thereof in a unit dosis form.
3. Use according to Claim 1, characterised in that the pharmaceutical preparation manufactured comprises 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrrahydro-1-methyl-pyridine or a pharmaceutically acceptable acid addition salt thereof in an amount of 500 µg to 600 mg/day, preferably 1.0 mg to 100 mg/day.
4. Use according to any of claims 1-3, characterised in that the pharmaceutical preparation manufactured is for the treatment of traumatic brain injury caused by physical forces acting on the scull or spinal column, ischaemia, stroke, arrested breathing, cardiac arrest, cerebral thrombosis or embolsm, neurological problem caused by AIDS, cerebral hemorrhage, encephalomyelitis, hydrocephalus, post-operative events, cerebral infections, concussions or elevated intracranial pressure and or for the treatment of the sequelae of such a condition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK123295 | 1995-11-06 | ||
| DK1232/95 | 1995-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2234824A1 true CA2234824A1 (en) | 1997-05-15 |
Family
ID=8102484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002234824A Abandoned CA2234824A1 (en) | 1995-11-06 | 1996-11-05 | Treatment of traumatic brain injury |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0866706A1 (en) |
| JP (1) | JPH11514654A (en) |
| KR (1) | KR19990067353A (en) |
| AU (1) | AU706594B2 (en) |
| BG (1) | BG63150B1 (en) |
| BR (1) | BR9611396A (en) |
| CA (1) | CA2234824A1 (en) |
| CZ (1) | CZ287441B6 (en) |
| EA (1) | EA000531B1 (en) |
| HU (1) | HUP9901051A2 (en) |
| IS (1) | IS4726A (en) |
| NO (1) | NO982036L (en) |
| NZ (1) | NZ321546A (en) |
| PL (1) | PL326490A1 (en) |
| SK (1) | SK58198A3 (en) |
| TR (1) | TR199800801T2 (en) |
| WO (1) | WO1997017074A1 (en) |
| ZA (1) | ZA969320B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR013096A1 (en) * | 1997-07-01 | 2000-12-13 | Lundbeck & Co As H | SALE OF ADDITION OF MALEIC ACID OF 5- (2-ETIL-2-H-TETRAZOL-5-IL) -1-METHYL-1,2,3,6-TETRAHIDROPIRIDINA, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT, ITS USE IN THERAPY AND METHOD OF PREPARATION OF THE SAME. |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8714789D0 (en) * | 1987-06-24 | 1987-07-29 | Lundbeck & Co As H | Heterocyclic compounds |
| US5328925A (en) * | 1989-02-22 | 1994-07-12 | Novo Nordisk A/S | Piperidine compounds and their use |
| IE922270A1 (en) * | 1991-07-26 | 1993-01-27 | Akzo Nv | Pyrazole derivatives |
| US5330994A (en) * | 1992-03-24 | 1994-07-19 | Warner-Lambert Company | Tetrahydropyridine isoxazoline derivatives |
-
1996
- 1996-11-05 JP JP9517762A patent/JPH11514654A/en active Pending
- 1996-11-05 CA CA002234824A patent/CA2234824A1/en not_active Abandoned
- 1996-11-05 AU AU74900/96A patent/AU706594B2/en not_active Ceased
- 1996-11-05 SK SK581-98A patent/SK58198A3/en unknown
- 1996-11-05 HU HU9901051A patent/HUP9901051A2/en unknown
- 1996-11-05 KR KR1019980703360A patent/KR19990067353A/en not_active Application Discontinuation
- 1996-11-05 PL PL96326490A patent/PL326490A1/en unknown
- 1996-11-05 NZ NZ321546A patent/NZ321546A/en unknown
- 1996-11-05 TR TR1998/00801T patent/TR199800801T2/en unknown
- 1996-11-05 BR BR9611396A patent/BR9611396A/en not_active Application Discontinuation
- 1996-11-05 EP EP96937193A patent/EP0866706A1/en not_active Ceased
- 1996-11-05 WO PCT/DK1996/000458 patent/WO1997017074A1/en not_active Application Discontinuation
- 1996-11-05 EA EA199800434A patent/EA000531B1/en not_active IP Right Cessation
- 1996-11-05 CZ CZ19981389A patent/CZ287441B6/en not_active IP Right Cessation
- 1996-11-06 ZA ZA969320A patent/ZA969320B/en unknown
-
1998
- 1998-04-27 IS IS4726A patent/IS4726A/en unknown
- 1998-05-05 NO NO982036A patent/NO982036L/en not_active Application Discontinuation
- 1998-05-22 BG BG102480A patent/BG63150B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA969320B (en) | 1997-05-30 |
| JPH11514654A (en) | 1999-12-14 |
| EA000531B1 (en) | 1999-10-28 |
| PL326490A1 (en) | 1998-09-28 |
| BR9611396A (en) | 1999-07-13 |
| EP0866706A1 (en) | 1998-09-30 |
| EA199800434A1 (en) | 1998-10-29 |
| AU706594B2 (en) | 1999-06-17 |
| NZ321546A (en) | 2000-12-22 |
| CZ138998A3 (en) | 1998-10-14 |
| HUP9901051A2 (en) | 2000-03-28 |
| SK58198A3 (en) | 1998-10-07 |
| NO982036D0 (en) | 1998-05-05 |
| WO1997017074A1 (en) | 1997-05-15 |
| MX9803432A (en) | 1998-09-30 |
| TR199800801T2 (en) | 1998-08-21 |
| NO982036L (en) | 1998-06-25 |
| IS4726A (en) | 1998-04-27 |
| CZ287441B6 (en) | 2000-11-15 |
| BG63150B1 (en) | 2001-05-31 |
| AU7490096A (en) | 1997-05-29 |
| KR19990067353A (en) | 1999-08-16 |
| BG102480A (en) | 1999-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3650733T2 (en) | Pharmaceutical preparations and medical uses of dioxopiperidine derivatives, in particular as an enhancer of the immune response and as antiviral and antibacterial agents | |
| EP0651642A1 (en) | Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity | |
| EP0615751B1 (en) | Use of tachykinin antagonists in the treatment of emesis | |
| JPH10508866A (en) | Oral composition containing ondansetron | |
| US5290783A (en) | Use of spiperone derivatives as immunosuppressant agents | |
| US6297262B1 (en) | Treatment of schizophrenia and psychosis | |
| US4835173A (en) | Method of medical treatment | |
| AU706594B2 (en) | Treatment of traumatic brain injury | |
| KR950010148B1 (en) | Medicaments for treatment on prevention of withdrawal syndrome | |
| EP0275668B1 (en) | Use of ketone derivatives in the treatment of cognitive disorders | |
| AU764304B2 (en) | Use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of major depressive disorders | |
| US20060135507A1 (en) | Therapeutic agent for overactive bladder involved in aging | |
| US20060269598A1 (en) | Antihistaminic/Decongestant/Anticholinergic Compositions and Methods of Use | |
| JP2005532274A (en) | A non-hormonal approach for male contraception | |
| US20060269597A1 (en) | Tannate Compositions and Methods of Use for the Treatment of Respiratory Tract Conditions | |
| EP0690715B1 (en) | Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses | |
| CA2022379A1 (en) | Medicaments | |
| MXPA98003432A (en) | Treatment of traumat cerebral damage | |
| US20030166667A1 (en) | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | |
| JPH01250319A (en) | Drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |